Nicole Drezner

987 total citations · 1 hit paper
13 papers, 430 citations indexed

About

Nicole Drezner is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Nicole Drezner has authored 13 papers receiving a total of 430 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Nicole Drezner's work include Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Nicole Drezner is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Lung Cancer Diagnosis and Treatment (3 papers). Nicole Drezner collaborates with scholars based in United States, Switzerland and Singapore. Nicole Drezner's co-authors include Richard Pazdur, Harpreet Singh, Julia A. Beaver, Pallavi S. Mishra‐Kalyani, Erica C. Nakajima, Youwei Bi, Dianne Spillman, Jiang Liu, Hong Zhao and Atiqur Rahman and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and The Oncologist.

In The Last Decade

Nicole Drezner

13 papers receiving 423 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC

2021 193 citations Erica C. Nakajima, Nicole Drezner et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Nicole Drezner United States	8	233	218	160	73	50	13	430
Mark T. J. van Bussel Netherlands	8	182 0.8×	165 0.8×	119 0.7×	52 0.7×	96 1.9×	11	344
Donna-Michelle Smith United Kingdom	9	213 0.9×	100 0.5×	151 0.9×	57 0.8×	41 0.8×	12	363
Laura Kirby Australia	8	245 1.1×	128 0.6×	169 1.1×	33 0.5×	30 0.6×	11	362
P. LoRusso United States	9	340 1.5×	311 1.4×	201 1.3×	80 1.1×	73 1.5×	21	510
Julio A. Peguero United States	12	368 1.6×	241 1.1×	133 0.8×	78 1.1×	28 0.6×	49	517
Özge Gümüşay Türkiye	11	164 0.7×	124 0.6×	100 0.6×	78 1.1×	27 0.5×	42	350
Jérôme Alexandre France	3	139 0.6×	174 0.8×	296 1.9×	78 1.1×	47 0.9×	4	445
Susanne Hedbom Germany	4	277 1.2×	120 0.6×	167 1.0×	63 0.9×	29 0.6×	5	463
Matteo Repetto Italy	10	159 0.7×	126 0.6×	131 0.8×	114 1.6×	20 0.4×	23	360
Ivana Sullivan Spain	14	509 2.2×	322 1.5×	218 1.4×	100 1.4×	26 0.5×	55	686

Countries citing papers authored by Nicole Drezner

Since Specialization

Citations

This map shows the geographic impact of Nicole Drezner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicole Drezner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicole Drezner more than expected).

Fields of papers citing papers by Nicole Drezner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicole Drezner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicole Drezner. The network helps show where Nicole Drezner may publish in the future.

Co-authorship network of co-authors of Nicole Drezner

This figure shows the co-authorship network connecting the top 25 collaborators of Nicole Drezner. A scholar is included among the top collaborators of Nicole Drezner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicole Drezner. Nicole Drezner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Duke, Elizabeth S., Diana Bradford, A. K. Sinha, et al.. (2024). US Food and Drug Administration Approval Summary: Eflornithine for High-Risk Neuroblastoma After Prior Multiagent, Multimodality Therapy. Journal of Clinical Oncology. 42(25). 3047–3057. 5 indexed citations

Vallejo, Jonathon, Harpreet Singh, Erin Larkins, et al.. (2024). Impact of Increasing PD-L1 Levels on Outcomes to PD-1/PD-L1 Inhibition in Patients With NSCLC: A Pooled Analysis of 11 Prospective Clinical Trials. The Oncologist. 29(5). 422–430. 5 indexed citations

Akinboro, Oladimeji, Nicole Drezner, Anup Amatya, et al.. (2023). US Food and Drug Administration Approval Summary: Nivolumab Plus Platinum-Doublet Chemotherapy for the Neoadjuvant Treatment of Patients With Resectable Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 41(17). 3249–3259. 23 indexed citations

Akinboro, Oladimeji, Vaibhav Kumar, Nicole Drezner, et al.. (2023). Trends in U.S and global patient enrollment from 2014 to 2022 in lung cancer clinical trials supporting marketing applications: An FDA analysis.. Journal of Clinical Oncology. 41(16_suppl). 1576–1576. 2 indexed citations

Barbato, Michael I., Diana Bradford, Yi Ren, et al.. (2023). FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation–Positive Low-Grade Glioma. Clinical Cancer Research. 30(2). 263–268. 33 indexed citations

Akinboro, Oladimeji, Jonathon Vallejo, Erica C. Nakajima, et al.. (2022). Outcomes of anti–PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non–small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.. Journal of Clinical Oncology. 40(16_suppl). 9000–9000. 37 indexed citations

Nakajima, Erica C., Yi Ren, Jonathon Vallejo, et al.. (2022). Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis.. Journal of Clinical Oncology. 40(16_suppl). 9001–9001. 37 indexed citations

Vellanki, Paz J., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Osimertinib for Adjuvant Treatment of Surgically Resected Non–Small Cell Lung Cancer, a Collaborative Project Orbis Review. Clinical Cancer Research. 27(24). 6638–6643. 42 indexed citations

Nakajima, Erica C., Nicole Drezner, Xiaoxue Li, et al.. (2021). FDA Approval Summary: Sotorasib for KRAS G12C -Mutated Metastatic NSCLC. Clinical Cancer Research. 28(8). 1482–1486. 193 indexed citations breakdown →

10.

Akinboro, Oladimeji, Jonathon Vallejo, Pallavi S. Mishra‐Kalyani, et al.. (2021). Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.. Journal of Clinical Oncology. 39(15_suppl). 9001–9001. 25 indexed citations

11.

Patel, Chirag, et al.. (2019). Pivotal Considerations for Optimal Deployment of Healthy Volunteers in Oncology Drug Development. Clinical and Translational Science. 13(1). 31–40. 7 indexed citations

12.

Drezner, Nicole, Kristina K. Hardy, Elizabeth Wells, et al.. (2016). Treatment of pediatric cerebral radiation necrosis: a systematic review. Journal of Neuro-Oncology. 130(1). 141–148. 19 indexed citations

13.

Drezner, Nicole & Roger J. Packer. (2016). The impact of molecular analysis on the survival of children with embryonal tumors.. PubMed. 5(1). 5–8. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact